NEW ZEALAND DATA SHEET

1. PRODUCT NAME Tenofovir disoproxil tablets (Teva) 245 mg NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains tenofovir disoproxil succinate 300.6 mg equivalent to tenofovir disoproxil 245 mg. Excipient with known effect: lactose For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Light blue, almond shaped, film coated tablets with dimensions of approximately 17.0 mm x 10.5 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Tenofovir disoproxil tablets in combination with other antiretroviral agents are indicated for the treatment of HIV- infected adults and paediatric patients 12 years of age and older. Tenofovir disoproxil tablets are indicated for the treatment of chronic hepatitis B in adults and in paediatric patients 12 years of age and older. 4.2 Dose and method of administration Adults: The recommended dose is one tablet once daily taken orally with or without food. Paediatric Patients ( 12 Years of Age and 35 kg): The recommended dose for paediatric patients (12 years of age and older), who weigh 35 kg, is one tablet once daily taken orally with or without food. The safety and efficacy of tenofovir disoproxil in patients under the age of 12 years have not been established. Tenofovir disoproxil tablets must not be administered to children under 12, until further data become available. Elderly: No data are available on which to make a dose recommendation for patients over the age of 65 years. The safety and efficacy of tenofovir disoproxil has not been established in patients over the age of 65 years. Caution should be exercised when administering Tenofovir disoproxil tablets to elderly patients until further data become available describing the disposition of tenofovir disoproxil in these patients. The greater frequency of decreased hepatic, renal or cardiac function in these patients, presence of any concomitant illnesses or the need for treatment with other medicinal products concomitantly with Tenofovir disoproxil tablets should be taken into consideration. Renal impairment: Tenofovir is eliminated by renal excretion and the exposure to tenofovir increases in patients with renal dysfunction. Dosing interval adjustment is required in all patients with creatinine clearance <50 ml/min (calculated using the Cockcroft Gault equation), as detailed in the following table. Version 1.1 1

Dosage Adjustment for Patients with Altered Creatinine Clearance Recommended 300 mg Dosing Interval Creatinine Clearance (ml/min) 1 50 30-49 10-29 Every 24 hours Every 48 hours Every 72 to 96 hours 1. Calculated with Cockcroft Gault equation. 2. Generally once weekly assuming three haemodialysis sessions a week of approximately 4 hours duration. Tenofovir disoproxil should be administered following completion of dialysis. Haemodialysis Patients Every 7 days or after a total of approximately 12 hours of dialysis 2 The proposed dose interval modifications are based on limited data and may not be optimal. The safety and efficacy of these dosing interval adjustment guidelines have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients. The pharmacokinetics of tenofovir have not been evaluated in non-haemodialysis patients with creatinine clearance <10 ml/min; therefore, no dosing recommendation is available for these patients. No data are available to make dose recommendations in paediatric patients 12 years of age and older with renal impairment. Hepatic impairment: There were no substantial alterations in tenofovir pharmacokinetics in patients with hepatic impairment compared with unimpaired patients. No change in tenofovir disoproxil dosing is required in patients with hepatic impairment. Chronic hepatitis B: Treatment with tenofovir disoproxil may be discontinued if there is HBsAg loss or HBsAg seroconversion, otherwise the optimal duration of treatment is unknown. 4.3 Contraindications Known hypersensitivity to tenofovir, tenofovir disoproxil succinate, or to any of the excipients in the film-coated tablets. Tenofovir disoproxil tablets must not be administered to children less than 12 years of age until further data become available. Tenofovir disoproxil tablets should not be administered concurrently with fixed dose combination tablets containing tenofovir disoproxil succinate, tenofovir alafenamide or adefovir dipivoxil. 4.4 Special warnings and precautions for use General Patients receiving Tenofovir disoproxil tablets or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases. Patients should be advised that antiretroviral therapies, including tenofovir disoproxil, have not been proven to prevent the risk of transmission of HIV or HBV to others through sexual contact or blood contamination. Appropriate precautions must continue to be used. Patients should also be informed that Tenofovir disoproxil tablets are not a cure for HIV infection. HIV antibody testing should be offered to all HBV-infected patients before initiating tenofovir disoproxil therapy. In the treatment of chronic hepatitis B, limited data are currently available in immuno-suppressed patients or those receiving immuno-suppressive regimens, orthotrophic liver transplant patients and Version 1.1 2

patients coinfected with the hepatitis C or D virus. As clinical studies have not included sufficient numbers of subjects to determine whether these patients respond differently to tenofovir disoproxil chronic hepatitis B therapy, such patients should be closely monitored. Use in children The safety and efficacy of tenofovir disoproxil in paediatric patients aged 12 to <18 years is supported by data from two randomised studies in which tenofovir disoproxil was administered to HIV-infected treatment experienced patients and patients with chronic hepatitis B. The safety and efficacy of tenofovir disoproxil has not been established in children less than 12 years of age. The clinical relevance of the long term effects of tenofovir disoproxil treatment on BMD are unknown, and at present the data on the reversibility of renal toxicity effects is limited. Therefore, a multidisciplinary approach is recommended to consider the benefit/risk balance of treatment. As hepatitis B is a chronic disease of the liver, ongoing clinical monitoring is recommended. Use in the elderly Tenofovir disoproxil has not been studied in patients over the age of 65. In general, dose selection for the elderly patient should be cautious, keeping in mind the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy (see section 4.2 Dose and method of administration). Impaired renal function Dosing interval adjustment is required in all patients with creatinine clearance <50 ml/min (see section 4.2 Dose and method of administration). The proposed dose interval modifications are based on limited data and may not be optimal. The safety and efficacy of these dosing interval adjustment guidelines have not been clinically evaluated, and so the potential benefit of tenofovir disoproxil therapy should be assessed against the potential risk of renal toxicity. Therefore, clinical response to treatment and renal function should be closely monitored in these patients. Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphataemia), has been reported in association with the use of tenofovir disoproxil (see section 4.8 Undesirable effects). Tenofovir disoproxil should be avoided with concurrent or recent use of a nephrotoxic agent. It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy and, as clinically appropriate, during tenofovir disoproxil therapy. Patients at risk for, or with a history of, renal dysfunction, including patients who have previously experienced renal events while receiving adefovir dipivoxil, should be routinely monitored for changes in serum creatinine and phosphorus. Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues alone or in combination, including tenofovir disoproxil, in the treatment of HIV infection. A majority of these cases have been reported in women. The preclinical and clinical data suggest that the risk of occurrence of lactic acidosis, a class effect of nucleoside analogues is low for tenofovir disoproxil. However, as tenofovir is structurally related to nucleoside analogues, this risk cannot be excluded. Caution should be exercised when administering tenofovir disoproxil to any patient, and particularly to those with known risk factors for liver disease. Treatment with tenofovir disoproxil should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity. Version 1.1 3

HIV and HBV co-infection Due to the risk of development of HIV resistance, tenofovir disoproxil should only be used as part of an appropriate antiretroviral combination regimen in HIV/HBV co-infected patients. Exacerbation of Hepatitis After Discontinuation of Treatment Discontinuation of anti-hbv therapy, including tenofovir disoproxil may be associated with severe acute exacerbations of hepatitis. Patients infected with HBV who discontinue tenofovir disoproxil should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, resumption of anti-hepatitis B therapy may be warranted. In patients with advanced liver disease or cirrhosis, discontinuation of anti-hepatitis B therapy is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation. Early Virologic Failure Clinical studies in HIV-infected patients have demonstrated that certain regimens that only contain 3 nucleoside reverse transcriptase inhibitors (NRTI) are generally less effective than triple drug regimens containing 2 NRTIs in combination with either a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor. In particular, early virological failure and high rates of resistance mutations have been reported in clinical studies of combinations of tenofovir, lamivudine and abacavir or tenofovir, lamivudine and didanosine. Triple nucleoside regimens should therefore be used with caution. Patients on a therapy utilizing a triple nucleoside-only regimen should be carefully monitored and considered for treatment modification. Immune Reconstitution Syndrome In HIV-infected patients with severe immune deficiency at the time of initiation of antiretroviral therapy, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of antiretroviral therapy. Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and Pneumocystis joroveci pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary. Autoimmune disorders have also been reported to occur in the setting of immune reconstitution; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment. Lipodystrophy In HIV infected patients redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving combination antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established. Bone Effects Bone toxicities including a reduction in bone mineral density (BMD) have been observed in studies in three animal species (see section 5.3 Preclinical data, Animal Toxicology). Clinically relevant bone abnormalities have not been seen in long term clinical studies in adults (>3 years). Bone abnormalities (infrequently contributing to fractures) may be associated with proximal renal tubulopathy (see section 4.8 Undesirable effects, Post-Marketing Experience). If bone abnormalities are suspected during therapy then appropriate consultation should be obtained. There is limited clinical experience with tenofovir disoproxil in paediatric patients. In a clinical study of HIV-1 infected paediatric patients 12 years of age and older (Study 0321), bone effects were similar to adult patients. Under normal circumstances BMD increases rapidly in this age group. In Version 1.1 4

this study, the mean rate of bone gain was less in the tenofovir disoproxil-treated group compared to the placebo group. Six patients treated with tenofovir disoproxil and one placebo treated patient had significant (>4%) lumbar spine BMD loss in 48 weeks. Markers of bone turnover in tenofovir disoproxil-treated paediatric patients 12 years of age and older suggest increased bone turnover, consistent with the bone effects observed in adults. The effects of tenofovir disoproxil-associated changes in BMD and biochemical markers on long-term bone health and fracture risk are unknown. In a clinical study (Study 115) conducted in paediatric subjects 12 years of age and older with chronic HBV infection, both the tenofovir disoproxil and placebo treatment arms experienced an overall increase in mean spine BMD, as expected for an adolescent population. The percent increase from baseline in spine BMD in tenofovir disoproxil-treated subjects was less than the increase observed in placebo-treated subjects. During the study, three subjects in the tenofovir disoproxil group and two subjects in the placebo group had a decrease of more than 4% in lumbar spine BMD. 4.5 Interaction with other medicines and other forms of interaction At concentrations substantially higher (~ 300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug metabolism mediated by any of the following human CYP450 isoforms: CYP3A4, CYP2D6, CYP2C9 or CYP2E1. However, a small (6%) but statistically significant reduction in metabolism of CYP1A substrate was observed. Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP450 mediated interactions involving tenofovir with other medicinal products is low (see section 5.2 Pharmacokinetic properties). Tenofovir is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. Co-administration of tenofovir disoproxil with drugs that are eliminated by active tubular secretion may increase serum concentrations of either tenofovir or the co-administered drug, due to competition for this elimination pathway. Drugs that decrease renal function may also increase serum concentrations of tenofovir. Tenofovir disoproxil has been evaluated in healthy volunteers in combination with abacavir, didanosine, efavirenz, emtricitabine, entecavir, indinavir, lamivudine (3TC), ledipasvir/sofosbuvir, lopinavir/ritonavir, methadone, nelfinavir, oral contraceptives, ribavirinn saquinavir/ritonavir, sofosbuvir and tacrolimus. The pharmacokinetic effects of co-administered drug on tenofovir pharmacokinetics and effects of tenofovir disoproxil on the pharmacokinetics of co-administered drug are summarised in the following tables. When unboosted atazanavir (400 mg) was co-administered with tenofovir disoproxil, atazanavir increased tenofovir C max by 14% and AUC by 24%. Similarly, lopinavir (400 mg)/ritonavir (100 mg) increased tenofovir AUC by 32%. Tenofovir disoproxil should only be administered with boosted atazanavir (ATZ 300 mg/rtv 100 mg). The safety and efficacy of this regimen has been substantiated over 48 weeks in a clinical study. Co-administration of tenofovir disoproxil with didanosine and atazanavir results in changes in the pharmacokinetics of didanosine and atazanavir that may be of clinical significance. The drug interaction between tenofovir disoproxil and didanosine is summarised in the following table. When administered with multiple doses of tenofovir disoproxil, the C max and AUC of didanosine 400 mg increased significantly. The mechanism of this interaction is unknown. When didanosine 250 mg enteric-coated capsules were administered with tenofovir disoproxil, systemic exposures to didanosine were similar to those seen with the 400 mg enteric-coated capsules alone under fasted conditions (see section 5.2 Pharmacokinetic properties). Version 1.1 5

Higher didanosine concentrations could potentiate didanosine-associated adverse events, including pancreatitis, lactic acidosis and neuropathy. Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil with didanosine at a dose of 400 mg daily. In patients weighing 60kg, the didanosine dose should be reduced to 250 mg when it is co-administered with tenofovir disoproxil. Data are not available to recommend a dose adjustment of didanosine for adult or paediatric patients weighing <60 kg. When co-administered, tenofovir disoproxil and didanosine EC may be taken under fasted conditions or with a light meal (<400 kcal, 20% fat). Co-administration of didanosine buffered tablet formulation with tenofovir disoproxil should be under fasted conditions. Coadministration of tenofovir disoproxil and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse events. Didanosine should be discontinued in patients who develop didanosineassociated adverse events. Coadministration of tenofovir disoproxil fumarate and ledipasvir/sofosbuvir or sofosbuvir/velpatasvir has been shown to increase tenofovir exposure. Patients receiving tenofovir disoproxil tablets should be monitored for adverse reactions associated with tenofovir disoproxil. Since tenofovir is primarily eliminated by the kidneys, co-administration of tenofovir disoproxil with drugs that reduce renal function or complete for active tubular secretion may increase serum concentrations of tenofovir and/or increase the concentrations of other renally eliminated drugs. Version 1.1 6

Drug Interactions: Changes in Pharmacokinetic Parameters for Tenofovir 1 in thepresence of the Co-administered Drug Coadministered drug Dose of Coadministered Drug (mg) N % Change of Tenofovir Pharmacokinetic Parameters 2 (90% CI) C max AUC C min Abacavir 300 once 8 NC Atazanavir 3 400 once daily x 14 days 33 14 ( 8 to 20) Didanosine (enteric-coated) Didanosine 250 or 400 once daily x 7 (buffered) 4 days 24 ( 21 to 28) 22 ( 15 to 30) 400 once 25 14 Efavirenz 600 once daily x 14 days 29 Emtricitabine 200 once daily x 7 days 17 Entecavir 1 mg once daily x 10 days Indinavir 800 three times daily x 7 days 28 13 14 ( 3 to 33) Lamivudine 150 twice daily x 7 days 15 Ledipasvir/Sofosbuvir 5,6 24 47 ( 37 to 58) Ledipasvir/Sofosbuvir 5,7 23 64 ( 54 to 74) Ledipasvir/Sofosbuvir 8 90/400 once daily x 10 15 79 days ( 56 to 104) Ledipasvir/Sofosbuvir 9 14 32 ( 25 to 39) Ledipasvir/Sofosbuvir 10 29 61 ( 51 to 72) Lopinavir/Ritonavir 400/100 twice daily x 14 days 35 ( 29 to 42) 50 ( 42 to 59) 98 ( 77 to 123) 40 ( 31 to 50) 65 ( 59 to 71) 24 32 ( 26 to 38) 47 ( 38 to 57) 59 ( 49 to 70) 163 ( 132 to 197) 91 ( 74 to 110) 115 ( 105 to 126) 51 ( 32 to 66) Methadone 11 40-110 once daily x 14 days 12 13 Nelfinavir 1250 twice daily for 14 days Oral Contraceptives 13 Ethinyl Estradiol/Norgestimate (Ortho-Tricyclen ) Once daily x 7 days 29 20 Ribavirin 600 once 22 NC Saquinavir/Ritonavir 1000/100 twice daily x 14 days Sofosbuvir 14 400 once daily 16 25 ( 8 to 45) 35 23 ( 16 to 30) Version 1.1 7

Sofosbuvir/Velpatasvir 15 24 55 ( 43 to 68) Sofosbuvir/Velpatasvir 16 29 55 ( 45 to 66) Sofosbuvir/Velpatasvir 17 15 77 ( 53 to 104) 400/100 once daily Sofosbuvir/Velpatasvir 18 24 36 ( 25 to 47) Sofosbuvir/Velpatasvir 19 24 44 ( 33 to 55) Sofosbuvir/Velpatasvir 20 30 46 ( 39 to 54) Tacrolimus 21 0.05 mg/kg twice daily x 7 days 21 13 ( 1 to 27) 30 ( 24 to 36) 39 ( 33 to 44) 81 ( 68 to 94) 35 ( 29 to 42) 40 ( 34 to 46) 40 ( 34 to 45) 39 ( 31 to 48) 52 ( 45 to 59) 121 ( 100 to 143) 45 ( 39 to 51) 84 ( 76 to 92) 70 ( 61 to 79) 1. Patients received Tenofovir disoproxil 245 mg once daily. 2. Increase = ; Decrease = ; No Effect = ; NC = Not Calculated 3. REYATAZ TM Prescribing Information (Bristol-Myers Squibb) 4. Includes 4 subjects weighing <60 kg receiving ddi 250 mg 5. Data generated from simultaneous dosing with ledipasvir/sofosbuvir. Staggered administration (12 hours apart) provide similar results. 6. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/tenofovir disoproxil 7. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/tenofovir disoproxil 8. Study conducted with tenofovir disoproxil/emtricitabine/efavirenz coadministered with ledipasvir/sofosbuvir 9. Study conducted with tenofovir disoproxil/emtricitabine/rilpivirine coadministered with ledipasvir/sofosbuvir 10. R-(active), S-and total methadone exposures were equivalent when dosed alone or with Tenofovir disoproxil. 11. Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported. 12. Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with Tenofovir disoproxil. 13. Study conducted with tenofovir disoproxil/emtricitabine/efavirenz coadministered with sofosbuvir 14. Subjects received tenofovir disoproxil 245 mg once daily as the combination product emtricitabine/tenofovir disoproxil 15. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/tenofovir disoproxil. 16. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/tenofovir disoproxil. 17. Study conducted with tenofovir disoproxil/emtricitabine/efavirenz coadministered with sofosbuvir/velpatasvir. 18. Study conducted with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil coadministered with sofosbuvir/velpatasvir. 19. Study conducted with tenofovir disoproxil/emtricitabine/rilpivirine coadministered with sofosbuvir/velpatasvir. 20. Administered as raltegravir + emtricitabine/tenofovir disoproxil. 21. Subjects received tenofovir disoproxil 300 mg once daily as the combination product emtricitabine/tenofovir disoproxil. Following multiple dosing to HIV- and HBV-negative subjects receiving either chronic methadone maintenance therapy or oral contraceptives, steady state tenofovir pharmacokinetics were similar to those observed in previous studies, indicating lack of clinically significant drug interactions between these agents and tenofovir disoproxil. In a study conducted in healthy volunteers dosed with a single 600 mg dose of ribavirin, no clinically significant drug interactions were observed between tenofovir disoproxil and ribavirin. Version 1.1 8

Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the presence of Tenofovir Coadministered drug Dose of Coadministered Drug (mg) Abacavir 300 once 8 12 ( 1 to 26) Atazanavir 2 400 once daily x 14 days 34 21 ( 27 to 14) Atazanavir 2 Atazanavir/Ritonavir 3 300/100 once daily x 42 day N % Change of Co-administered Drug Pharmacokinetic Parameters 1 (90% CI) C max AUC C min 25 ( 30 to 19) NA 40 ( 48 to 32) 10 28 ( 50 to 5) 3 25 ( 42 to 3) 3 23 ( 46 to 10) 3 Efavirenz 600 once daily x 14 days 30 Emtricitabine (Emtriva) Entecavir 1 mg once daily x 10 days Indinavir 800 three times daily x 7 days 200 once daily x 7 days 17 20 ( 12 to 29) 28 13 ( 11 to 15) 12 11 ( 30 to 12) Lamivudine 150 twice daily x 7 days 15 24 ( 34 to 12) Ledipasvir Sofosbuvir GS-331007 4 Ledipasvir Sofosbuvir GS-331007 4 Ledipasvir Sofosbuvir GS-331007 4 Ledipasvir Sofosbuvir GS-331007 4 Lopinavir/Ritonavir Ledipasvir/Sofosbuvir 90/400 once daily x 10 days 5,6 Ledipasvir/Sofosbuvir 90/400 once daily x 10 days 5,7 Ledipasvir/Sofosbuvir 90/400 13 once daily x 10 days 8 Ledipasvir/Sofosbuvir 90/400 once daily x 10 days 9 Lopinavir/Ritonavir 400/100 twice daily x 14 days 24 68 ( 54 to 84) 96 ( 74 to 121) 118 ( 91 to 150) N/A 17 ( 12 to 23) 31 ( 25 to 36) 42 ( 34 to 49) 23 37 27 ( 48 to 25) ( 35 to 18) 15 34 ( 41 to 25) 34 ( 41 to 25) 34 ( 43 to 24) N/A 14 N/A 24 13 Methadone 10 40-110 once daily x 14 days 11 Nelfinavir M8 Metabolite 1250 twice daily for 14 days 29 Version 1.1 9

Oral Contraceptives 12 Ethinyl Estradiol/Norgestimate (Ortho-Tricyclen ) Once daily x 7 days 20 Ribavirin 600 once 22 NA Saquinavir/Ritonavir Sofosbuvir GS-331007 4 Tacrolimus 8 Saquinavir/Ritonavir 1000/100 twice daily x 14 days 32 22 ( 6 to 41) Sofosbuvir 400 once 16 19 daily x 10 days 14 ( 40 to 10) 0.05 mg/kg twice daily x 7 days 23 ( 30 to 16) 29 7 ( 12 to 48) 47 7 ( 23 to 76) 23 ( 3 to 46) N/A N/A 21 1. Increase = ; Decrease = ; No Effect = ; NA = Not Applicable 2. REYATAZ Prescribing Information (Bristol-Myers Squibb) 3. In HIV-infected patients, addition of tenofovir disoproxil to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and C min values of atazanavir that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone (REYATAZ March 2004 United States Package Insert) 4. The predominant circulating nucleoside metabolite of sofosbuvir 5. Data generated from simultaneous dosing with ledipasvir/sofosbuvir. Staggered administration (12 hours apart) provide similar results 6. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/tenofovir disoproxil 7. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/tenofovir disoproxil 8. Study conducted with tenofovir disoproxil/emtricitabine/efavirenz) coadministered with ledipasvir/sofosbuvir 9. Study conducted with tenofovir disoproxil/emtricitabine/rilpivirine) coadministered with ledipasvir/sofosbuvir 10. R-(active), S-and total methadone exposures were equivalent when dosed alone or with Tenofovir disoproxil. 11. Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported. 12. Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with Tenofovir disoproxil. 13. Increases in AUC and C min are not expected to be clinically relevant; hence no dose adjustments are required when tenofovir disoproxil and ritonavir-boosted saquinavir are coadministered. 14. Study conducted with tenofovir disoproxil/emtricitabine/efavirenz coadministered with sofosbuvir 15. Subjects received tenofovir disoproxil 245 mg once daily as the combination product emtricitabine/tenofovir disoproxil. Drug Interactions: Pharmacokinetic Parameters for Didanosine in the Presence of Tenofovir disoproxil Didanosine 1 Dose (mg)/ Method of Administration 2 Buffered tablets 400 once daily 4 x 7 days Enteric coated capsules Tenofovir Method of Administration 2 Fasted 1 hour after didanosine 400 once, fasted With food, 2 hr after didanosine 400 once, with food Simultaneously with didanosine N % Difference (90% CI) vs. Didanosine 400 mg alone, Fasted 3 C max 14 28 ( 11 to 48) 26 48 ( 25 to 76) 26 64 ( 41 to 89) AUC 44 ( 31 to 59) 48 ( 31 to 67) 60 ( 44 to 79) Version 1.1 10

250 once, fasted With food, 2 hr after didanosine 250 once, fasted Simultaneously with didanosine 250 once, with food Simultaneously with didanosine 1. See Precautions regarding use of didanosine with tenofovir disproxil. 2. Administration with food was with a light meal (~373 kcal, 20% fat). 3. Increase = ; Decrease = ; No Difference = 4. Includes 4 subjects weighing <60 kg receiving ddi 250 mg. Paediatric population Interaction studies have only been performed in adults. 28 10 ( 22 to 3) 28 14 (0 to 31) 28 29 ( 39 to 18) 11 ( 23 to 2) 4.6 Fertility, pregnancy and lactation Impairment of fertility Male and female rat fertility and mating performance or early embryonic development were unaffected by an oral tenofovir disoproxil dose (490 mg/kg/day) that achieved systemic drug exposures that were in excess of the value in humans receiving the therapeutic dose (5-fold based on plasma AUC). There was, however, an alteration of the oestrous cycle in female rats. Use in pregnancy Pregnancy Category B3 No clinical data are available for pregnant women being treated with tenofovir disoproxil. Reproductive toxicity studies performed in rats and rabbits did not reveal any evidence of harm to the foetus due to tenofovir at respective exposures (AUC) of 4-13 and 66- fold the human exposure. Subcutaneous treatment of pregnant rhesus monkeys with a dose of 30 mg/kg/day of the tenofovir base during the last half of pregnancy resulted in reduced foetal serum phosphorus concentrations. Because animal reproduction studies are not always predictive of human response, tenofovir disoproxil should be used during pregnancy only if clearly needed. Use in lactation In animal studies tenofovir was excreted in milk after oral administration of tenofovir disoproxil (rats) and after subcutaneous administration of tenofovir base (non-human primates). In humans, samples of breast milk obtained from five HIV-1 infected mothers show that tenofovir is secreted in human milk at low concentrations (estimated neonatal concentrations 128 to 266 times lower than the tenofovir IC 50 (50% maximal inhibitory concentration). Tenofovir associated risks, including the risk of developing viral resistance to tenofovir, in infants breastfed by mothers being treated with tenofovir disoproxil are unknown. It is recommended that HIV and HBV infected women do not breast-feed their infants in order to avoid transmission of HIV and HBV to the infant. 4.7 Effects on ability to drive and use machines No studies on the effects on ability to drive or use machines have been performed. However, patients should be informed that dizziness has been reported during treatment with tenofovir disoproxil. 4.8 Undesirable effects From Clinical Studies Clinical Trials in Adult Patients with HIV Infection More than 12,000 patients have been treated with tenofovir disoproxil alone or in combination with other antiretroviral medicinal products for periods of 28 days to 215 weeks in Phase I-III clinical trials and expanded access studies. A total of 1,544 patients have received tenofovir disoproxil 245 mg Version 1.1 11

once daily in Phase I-III clinical trials; over 11,000 patients have received tenofovir disoproxil in expanded access studies. Treatment-Experienced Adult Patients Treatment-Emergent Adverse Events: The most common adverse events that occurred in patients receiving tenofovir disoproxil with other antiretroviral agents in clinical trials were mild to moderate gastrointestinal events, such as nausea, diarrhoea, vomiting and flatulence. Less than 1% of patients discontinued participation in the clinical studies due to gastrointestinal adverse events (Study 907). A summary of treatment-emergent adverse events that occurred during the first 48 weeks of Study 907 is provided below. Selected Treatment-Emergent Adverse Events (Grades 2 4) Reported in 3% in any Treatment Group in Study 907 (0-48 weeks) Body as a Whole Asthenia Pain Headache Abdominal Pain Back Pain Chest Pain Fever Digestive System Diarrhoea Nausea Vomiting Anorexia Dyspepsia Flatulence Tenofovir Disoproxil (N=368) (Week 0-24) 7% 7% 5% 4% 3% 3% 2% 11% 8% 4% 3% 3% 3% Placebo (N=182) (Week 0-24) 6% 7% 5% 3% 3% 1% 2% 10% 5% 1% 2% 2% 1% Tenofovir Disoproxil (N=368) (Week 0-48) 11% 12% 8% 7% 4% 3% 4% 16% 11% 7% 4% 4% 4% Placebo Crossover to Tenofovir Disoproxil (N=170) (Week 24-48) Respiratory Pneumonia 2% 0% 3% 2% Nervous System Depression Insomnia Peripheral Neuropathy 1 Dizziness Skin and Appendage Rash Event 2 Sweating 4% 3% 3% 1% 5% 3% Musculoskeletal Myalgia 3% 3% 4% 1% Metabolic Weight Loss 2% 1% 4% 2% 1. Peripheral neuropathy includes peripheral neuritis and neuropathy. 2. Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash. 3% 2% 3% 3% 4% 2% 8% 4% 5% 3% 7% 3% 1% 4% 2% 6% 2% 2% 2% 11% 7% 5% 1% 2% 1% 4% 4% 2% 1% 1% 1% Version 1.1 12

Laboratory Abnormalities Laboratory abnormalities observed in this study occurred with similar frequency in the tenofovir disoproxil and placebo-treated groups. A summary of Grade 3 and 4 laboratory abnormalities is provided in the table below. Grade 3 / 4 Laboratory Abnormalities Reported in 1% of Tenofovir disoproxil-treated Patients in Study 907 (0 48 weeks) TENOFOVIR DISOPROXIL (N=368) (Week 0 24) Placebo (N=182) (Week 0 24) TENOFOVIR DISOPROXIL (N=368) (Week 0 48) Placebo Crossover to TENOFOVIR DISOPROXIL (N=170) (Week 24 48) (%) (%) (%) (%) Any Grade 3 Laboratory Abnormality 25% 38% 35% 34% Triglycerides (>750 mg/dl) 8% 13% 11% 9% Creatine Kinase (M: >990U/L) (F: >845 U/L) 7% 14% 12% 12% Serum Amylase (>175 U/L) 6% 7% 7% 6% Urine Glucose ( 3+) 3% 3% 3% 2% AST (M: > 180 U/L) (F: > 170 U/L) ALT (M: >215 U/L) (F: >170 U/L) 3% 3% 4% 5% 2% 2% 4% 5% Serum Glucose (>250 U/L) 2% 4% 3% 3% Neutrophils (<750 mg/dl) 1% 1% 2% 1% Treatment-Naïve Adult Patients Treatment-Emergent Adverse Events: In a double-blind active controlled study in which 600 treatment-naïve patients received tenofovir disoproxil (N=299) or d4t (N=301) in combination with lamivudine and efavirenz for 144 weeks (Study 903), the adverse reactions seen were generally consistent, with the addition of dizziness, with those seen in treatment-experienced patients. Mild adverse events (Grade 1) were common with a similar incidence in both arms, and included dizziness, diarrhoea and nausea. Version 1.1 13

Selected Treatment-Emergent Adverse Events (Grades 2 4) Reported in 5% in any Treatment Group in Study 903 (0 144 weeks) Body as a Whole Headache Pain Back Pain Fever Abdominal Pain Asthenia Digestive System Diarrhoea Nausea Vomiting Dyspepsia Tenofovir Disoproxil+3TC+EFV d4t+3tc+efv N=299 N=301 14% 13% 9% 8% 7% 6% 11% 8% 5% 4% 17% 12% 8% 7% 12% 7% 13% 9% 9% 5% Metabolic Disorders Lipodystrophy 1% 8% Musculoskeletal Arthralgia Myalgia Nervous System Depression Anxiety Insomnia Dizziness Peripheral Neuropathy 1 5% 3% 11% 6% 5% 3% 1% Respiratory Pneumonia 5% 5% Skin and Appendage Rash Event 2 18% 12% 1. Peripheral neuropathy includes peripheral neuritis and neuropathy 2. Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash Laboratory Abnormalities With the exception of triglyceride elevations that were more common in the d4t group (14%) compared with tenofovir disoproxil (3%), laboratory abnormalities observed in this study occurred with similar frequency in the tenofovir disoproxil and d4t treatment arms. A summary of Grade 3 and 4 laboratory abnormalities is provided in the table below. 7% 5% 10% 6% 8% 6% 5% Version 1.1 14

Grade 3/4 Laboratory Abnormalities Reported in 1% of Tenofovir disoproxil-treated Patients in Study 903 (0 144 weeks) Tenofovir Disoproxil+3TC+EFV d4t+3tc+efv N=299 N=301 Any Grade 3 Laboratory Abnormality 36% 42% Creatine Kinase (M: >990U/L) (F: >845 U/L) 12% 12% Serum Amylase (>175 U/L) 9% 8% AST (M: > 180 U/L) (F: > 170 U/L) ALT (M: >215 U/L) (F: >170 U/L) 5% 7% 4% 5% Haematuria (>100 RBC/HPF) 7% 7% Neutrophil (<750/mm 3 ) 3% 1% Triglyceride (>750 mg/dl) 3% 13% Study 934 - Treatment Emergent Adverse Events: Study 934 was an open-label active- controlled study in which 511 antiretroviral-naïve patients received either tenofovir disoproxil + EMTRIVA administered in combination with efavirenz (N=257) or Combivir (lamivudine/zidovudine) administered in combination with efavirenz (N=254). Adverse events observed in this study were generally consistent with those seen in previous studies in treatment-experienced or treatmentnaïve patients. Adverse events leading to study drug discontinuation occurred in significantly smaller number of patients in the TRUVADA (tenofovir disoproxil/emtricitabine) group compared to the Combivir group (5% vs 11%, p=0.010). The most frequently occurring adverse event leading to study drug discontinuation was anaemia (including decreased haemoglobin), no patient in the TRUVADA group and 6% of patients in the Combivir group. Frequency of Adverse Reactions to EMTRIVA and/or Tenofovir disoproxil (Grade 2 4) Occurring in 3% of Patients Receiving EMTRIVA and Tenofovir disoproxil (or TRUVADA) in Study 934 (0-144 Weeks) 1 Adverse Reaction Gastrointestinal Disorders Diarrhoea Nausea Nervous System Disorders Headache Dizziness Psychiatric Disorders Insomnia Abnormal Dreams TRUVADA 2 +EFV N=257 9% 9% Combivir + EFV N=254 Skin and Subcutaneous Tissue Disorders Rash 5% 4% 1. Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug. 2. Patients received Tenofovir disoproxil + EMTRIVA up to week 96 and switched to TRUVADA from week 96 to 144. Laboratory Abnormalities Laboratory abnormalities observed in this study were generally consistent with those seen in previous studies. 6% 8% 5% 4% 5% 7% 5% 7% 7% 3% Version 1.1 15

Grade 3/4 Laboratory Abnormalities Reported in >1% of Patients in Either Treatment Group, Study 934 (0 144 weeks) TRUVADA 1 + EFV N=254 Combivir + EFV N=251 Any Grade 3 Laboratory Abnormality 30% 26% Creatine Kinase (M: >990 U/L) (F: >845 U/L) 9% 7% Serum Amylase (>175 U/L) 8% 4% AST (M: >180 U/L) (F: >170 U/L) 3% 3% ALT (M: >215 U/L) 2% 3% (F: >170 U/L) Hyperglycaemia (>250 mg/dl) 2% 1% Haematuria (>75 RBC/HPF) 3% 2% Neutrophil (<750/mm 3 ) 3% 5% Triglyceride (>750 mg/dl) 5% 3% Haemoglobin (<7.0 g/dl) 0% 2% 1. Patients received Tenofovir disoproxil + EMTRIVA up to week 96 and switched to TRUVADA from week 96 to 144. Clinical Trials in Paediatric Patients 12 Years of Age and Older with HIV Infection Assessment of adverse reactions is based on 1 randomised study (study 321) in 87 HIV-infected paediatric patients (12 to 18 years of age) who received treatment with tenofovir disoproxil (n=45) or placebo (n=42) in combination with other antiretroviral agents for 48 weeks. The adverse reactions observed in paediatric patients 12 years of age and older who received treatment with tenofovir disoproxil were consistent with those observed in clinical studies in adults. Bone effects similar to those seen in adults were observed in this study (see Special warnings and precautions for use). Clinical Trials in Adult Patients with Hepatitis B Assessment of adverse reactions is based on experience in 2 double-blind comparative controlled studies (0102 and 0103) in which 641 patients with chronic hepatitis B and compensated liver disease received treatment with tenofovir disoproxil 245 mg daily (n=426) or HEPSERA 10 mg daily (n=215) for 48 weeks. The adverse reactions with suspected (at least possible) relationship to treatment are listed below by body system organ class and frequency. Gastrointestinal disorders: Common: nausea Version 1.1 16

Most Frequent (>5%) Treatment-Emergent Adverse Events of Any Severity (Integrated RAT analysis set; 48-week Data from Studies 102 and 103) AEs by Preferred Term a (n, %) b Overall TDF (N=426) Overall ADV (N=215) Any Adverse Event 317 ( 74.4%) 158 ( 73.5%) Headache 55 ( 12.9%) 30 ( 14.0%) Nasopharyngitis 42 ( 9.9%) 24 ( 11.2%) Nausea 40 ( 9.4%) 6 ( 2.8%) Fatigue 36 ( 8.5%) 16 ( 7.4%) Abdominal Pain Upper 30 ( 7.0%) 11 ( 5.1%) Back Pain 30 ( 7.0%) 10 ( 4.7%) Diarrhoea 28 ( 6.6%) 11 ( 5.1%) Dizziness 24 ( 5.6%) 7 ( 3.3%) Procedural Pain 16 ( 3.8%) 12 ( 5.6%) Pharyngolaryngeal Pain 15 ( 3.5%) 11 ( 5.1%) Upper Respiratory Tract Infection 13 ( 3.1%) 11 ( 5.1%) a Events coded using MedDRA dictionary version 9.1. b Subjects are counted once only for each system organ class and preferred term, counting the most severe occurrence. Laboratory Abnormalities A summary of Grade 3 and 4 laboratory abnormalities is provided below. Grade 3/4 Laboratory Abnormalities Reported in 1% of tenofovir disoproxil-treated Patients in Studies 0102 and 0103 (0-48 weeks) TENOFOVIR DISOPROXIL (N=426) HEPSERA (N=215) Any Grade 3 Laboratory Abnormality 19% 13% Creatine Kinase (M: >990 U/L; F: >845 U/L) 2% 3% Serum Kinase (>175 U/L) 4% 1% Glycosuria ( 3+) 3% < 1% AST (M: >180 U/L; F: >170 U/L) 4% 4% ALT (M: >215 U/L; F: >170 U/L) 10% 6% Treatment beyond 48 weeks: The adverse reactions observed with continued treatment for 384 weeks were consistent with the safety profile of tenofovir disoproxil. Grade 3/4 laboratory abnormalities were similar in nature and frequency in patients continuing treatment for up to 384 weeks in these studies. Nucleos(t)ide-Experienced Patients: No new adverse reactions to tenofovir disoproxil were identified in those patients in studies 0102, 0103 and 0106 and 0121 who had been previously treated with HEPSERA, lamivudine or other nucleoside analogs (n=493). Patients with Decompensated Liver Disease: No new adverse reactions to tenofovir disoproxil were identified from a double-blind active-controlled study (0108) in which patients with decompensated liver disease received treatment with tenofovir disoproxil (n=45) for 48 weeks. Among the 45 subjects receiving tenofovir disoproxil, the most frequently reported treatment-emergent adverse reactions of any severity were abdominal pain (22%), nausea (20%), insomnia (18%), pruritus (16%), vomiting (13%), dizziness (13%), and pyrexia (11%). Two of 45 (4%) subjects died through Week 48 of the study due to progression of liver disease. Three of 45 (7%) subjects discontinued treatment due to an adverse event. Four of 45 (9%) subjects experienced a confirmed increase in serum creatinine of 0.5 mg/dl (1 subject also had a confirmed serum phosphorus < 2mg/dL through Week 48). Three of these subjects (each of whom had a Child- Pugh score 10 and MELD score 14 at entry) developed renal failure. Because both tenofovir disoproxil and decompensated Version 1.1 17

liver disease may have an impact on renal function, the contribution of tenofovir disoproxil to renal impairment in this population is difficult to ascertain. One of 45 subjects experienced an on-treatment hepatic flare during the 48 Week study. At week 168, in this population of patients with decompensated liver disease, the rate of death was of 13% (6 of 45) in the tenofovir disoproxil group, 11% (5 of 45) in the emtricitabine plus tenofovir disoproxil group and 14% (3 of 22) in the entecavir group. The rate of serious hepatocellular carcinoma was 18% (8 of 45) in the tenofovir disoproxil group, 7% (3 of 45) in the emtricitabine plus tenofovir disoproxil group and 9% (2 of 22) in the entecavir group. The rate of serious ascites, which was experienced in 7% (3 of 45) in the tenofovir disoproxil group, 7% ( 3 of 45) in the emtricitabine plus tenofovir disoproxil group and 5% (1 of 22) in the entecavir group. The rate of serious hepatic encephalopathy was 7% (3/45) in the tenofovir disoproxil group, 2% (1 of 45) in the emtricitabine plus tenofovir disoproxil group, and 9% (2 of 22) in the entecavir group (see Clinical trials). Clinical Trials in Paediatric Patients 12 Years of Age and Older with HBV Infection Assessment of adverse reactions is based on 1 randomised study (study 0115) in 106 paediatric patients (12 to < 18 years of age) infected with chronic hepatitis B receiving treatment with tenofovir disoproxil (n=52) or placebo (n=54) for 72 weeks. The adverse reactions observed in paediatric patients who received treatment with tenofovir disoproxil were consistent with those observed in clinical studies in adults (see Undesirable effects). Post Marketing Experience In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of tenofovir disoproxil. Because these events have been reported voluntarily from a population of unknown size, estimates of frequency cannot be made. Immune System Disorders: Allergic reaction (including angioedema) Metabolism and Nutrition Disorders: Hypokalaemia, hypophosphataemia, lactic acidosis Respiratory, Thoracic, and Mediastinal Disorders: Dyspnoea Gastrointestinal Disorders: Increased amylase, abdominal pain, pancreatitis, Hepatobiliary Disorders: Hepatic steatosis, increased liver enzymes (most commonly AST, ALT, gamma GT), hepatitis Skin and Subcutaneous tissue disorders: Rash Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis, muscular weakness, myopathy, osteomalacia (manifested as bone pain and infrequently contributing to fractures) Renal and Urinary Disorders: Increased creatinine, renal insufficiency, renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, nephrogenic diabetes insipidus, proteinuria, acute tubular necrosis, polyuria, interstitial nephritis (including acute cases). Version 1.1 18

General Disorders and Administration Site Conditions: Asthenia The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia (manifested as bone pain and infrequently contributing to fractures), hypokalaemia, muscular weakness, myopathy, hypophosphataemia. These events are not considered to be causally associated with tenofovir disoproxil therapy in the absence of proximal renal tubulopathy. Immune Reconstitution Syndrome: In HIV-infected patients with severe immune deficiency at the time of initiation of antiretroviral therapy, an inflammatory reaction to infectious pathogens (active or inactive) may arise (see section 4.4 Special warnings and precautions for use). In HBV infected patients, clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of HBV therapy (see section 4.4 Special warnings and precautions for use). Adverse reactions attendant to class: Nephrotoxicity (elevation in serum creatinine and urine protein, and decrease in serum phosphorus) is the dose-limiting toxicity associated with other nucleotide analogues (cidofovir and high doses of adefovir dipivoxil evaluated for HIV disease (60 mg and 120 mg)). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/ 4.9 Overdose Clinical experience of doses higher than the therapeutic dose of tenofovir disoproxil 245 mg is available from two studies. In one study, intravenous tenofovir, equivalent to 16.7 mg/kg/day of tenofovir disoproxil fumarate, was administered daily for 7 days. In the second study, 600 mg of tenofovir disoproxil fumarate was administered to patients orally for 28 days. No unexpected or severe adverse reactions were reported in either study. The effects of higher doses are not known. If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8 Undesirable effects and section 4.4 Special warnings and precautions for use), and standard supportive treatment applied as necessary. Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. Following a single 245 mg dose of tenofovir disoproxil, a four-hour haemodialysis session removed approximately 10% of the administered tenofovir dose. For information on the management of overdose, contact the Poison Information Centre on 0800 764 766 (New Zealand). 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Antivirals, ATC code J05AF07 Mechanism of action Tenofovir disoproxil succinate is a salt of an oral prodrug of tenofovir, a nucleoside monophosphate (nucleotide) analogue and obligate chain terminator with activity against HIV reverse transcriptase and HBV polymerase. Tenofovir is converted to the active metabolite, tenofovir diphosphate, by constitutively expressed cellular enzymes through two phosphorylation reactions. This conversion occurs in both resting Version 1.1 19

and activated T cells. Tenofovir diphosphate has an intracellular half-life of 10 hours in activated and 50 hours in resting peripheral blood mononuclear cells (PBMCs). Tenofovir diphosphate inhibits viral polymerases by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ. At concentrations of up to 300 µm, tenofovir shows no effect on the synthesis of mitochondrial DNA (human liver, skeletal muscle and renal proximal tubular epithelial cells) or lactic acid production (human liver and skeletal muscle cells) in vitro. Pharmacodynamic effects Tenofovir has in vitro antiviral activity against retroviruses and hepadnaviruses. Anti-HIV-1 activity in vitro The in vitro antiviral activity of tenofovir against laboratory and clinical isolates of HIV was assessed in lymphoblastoid cell lines, primary monocyte/ macrophage cells and peripheral blood lymphocytes. The IC 50 (50% inhibitory concentration) for tenofovir was in the range of 0.04 µm to 8.5 µm. In drug combination studies of tenofovir with nucleoside and non-nucleoside analogue inhibitors of HIV reverse transcriptase, and protease inhibitors, additive to synergistic effects were observed. In addition, tenofovir has also been shown to be active in vitro against HIV-2, with similar potency as observed against HIV-1. Tenofovir shows activity within three fold of wild-type IC 50 against recombinant HIV-1 expressing didanosine resistance (L74V), zalcitabine resistance (T69D), or multinucleoside drug resistance (Q151M complex) mutations in reverse transcriptase. Tenofovir shows slightly increased activity against HIV-1 expressing the abacavir/lamivudine resistance mutation M184V. The activity of tenofovir against HIV-1 strains with thymidine analog-associated mutations (thymidine-associated mutations) appears to depend on the type and number of these resistance mutations. In the presence of mutation T215Y, a twofold increase of the IC 50 was observed. In 10 samples which had multiple thymidine-associated mutations (mean 3.4), a mean 3.7-fold increase of the IC 50 was observed (range 0.8 to 8.4). There are insufficient data at this time to correlate specific thymidine-associated mutation patterns with reduced susceptibility to tenofovir. Multinucleoside resistant HIV-1 with T69S double insertions have reduced susceptibility to tenofovir (IC 50 >10-fold compared with wild type). Tenofovir shows activity against non- nucleoside reverse transcriptase inhibitor resistant HIV-1 with K103N or Y181C mutations. Cross-resistance to protease inhibitor resistance mutations is not expected due to the different viral enzymes targeted. Strains of HIV-1 with reduced susceptibility to tenofovir have been selected in vitro.the selected viruses express a K65R mutation in RT and showed 3 to 4-fold reduced susceptibility to tenofovir. The K65R mutation in RT also results in reduced susceptibility to zalcitabine, didanosine, stavudine (d4t), abacavir, and lamivudine (14-, 4-, 2-, 3-, and 25-fold, respectively). In addition, a K70E substitution in HIV-1 reverse transcriptase has been selected by tenofovir and results in low-level reduced susceptibility tenofovir. This substitution is also associated with reduced susceptibility to abacavir, didanosine, emtricitabine and lamivudine. Anti-Hepatitis B Virus Activity In Vitro The in vitro antiviral activity of tenofovir against laboratory strains of HBV was assessed in the HepG2 2.2.15 cell line. The EC 50 values for tenofovir were in the range 0.14 to 1.5 µm, with CC 50 (50% cytotoxicity concentration) values > 100 µm. Tenofovir diphosphate inhibits recombinant HBV polymerase with a K i (inhibition constant) of 0.18 µm. In in vitro drug combination studies of tenofovir with nucleoside anti- HBV reverse transcriptase inhibitors lamivudine, telbivudine and entecavir, additive anti-hbv activity was observed. Additive to slightly synergistic effects were observed with the combination of tenofovir and emtricitabine. Version 1.1 20